TRP_1170x120_12-19-19

iNova Pharmaceuticals

Valeant to sell iNova Pharmaceuticals for $930 million

Valeant to sell iNova Pharmaceuticals for $930 million

LAVAL, Quebec — Valeant Pharmaceuticals International Inc. plans to sell its iNova Pharmaceuticals unit for $930 million in cash to help pay down debt. Valeant said Thursday that iNova, whose portfolio includes prescription drugs and over-the-counter health products, is being sold to a company jointly owned by funds of Pacific Equity Partners and Carlyle Group LP.